Aβ-IN-6 is an orally active compound exhibiting anti-inflammatory, antioxidant, and anti-oligomeric activities, with significant implications for Alzheimer's disease (AD) research [1]. It effectively reduces the release of pro-inflammatory cytokines from microglia cells, promotes Nrf2 nuclear translocation, and impedes the formation of Aβ oligomers. Furthermore, Aβ-IN-6 demonstrates a stable neuroprotective effect by modulating redox-sensitive signaling pathways in an in vivo oxidative stress model.

Aβ-IN-6（化合物4；1-20μM；24小时）在浓度5μM起对小胶质细胞活性产生显著降低[1]。同一化合物在浓度范围1.25-40μM，24小时处理后，对SH-SY5Y神经母细胞瘤细胞在2.5μM以上浓度显示出显著细胞毒性[1]。Aβ-IN-6以2.5μM浓度作用3小时，有效引发Nrf2的核内转移[1]。该化合物在2.5μM浓度下，显著抑制LPS刺激所引起的细胞因子及NLRP3 mRNA水平上升[1]。预处理浓度为1及2.5μM，作用1小时后结合LPS刺激24小时的Aβ-IN-6，能显著减少LPS引导的TNF-α和IL-1β释放[1]。在t-BuOOH（50μM；30分钟）处理前，Aβ-IN-6（2.5μM；24小时）预处理能够降低ROS生成，其抑制效果约为18%[1]。

Aβ-IN-6（化合物4；10 µM；混入标准饲料）能够有效降低D-spastin功能缺失模型神经退行性病变幼虫的肌肉和大脑中升高的ROS水平，恢复至Spastin果蝇模型对照组水平[1]。